Atorvastatin inhibits plaque development and adventitial neovascularization in ApoE deficient mice independent of plasma cholesterol levels

Atherosclerosis

Volumn 214, Issue 2, 2011, Pages 295-300

  Bot, Ilze ^a   Jukema, J Wouter ^b   Lankhuizen, Inge M ^a   van Berkel, Theo J C ^a   Biessen, Erik A L ^a,c  

^a LEIDEN UNIVERSITY   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Atherosclerosis; Cholesterol; Endothelial cell; Neovascularization; Statins

Indexed keywords

APOLIPOPROTEIN E; ATORVASTATIN; CD31 ANTIGEN; CHOLESTEROL;

ADVENTITIAL NEOVASCULARIZATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROTIC PLAQUE; CAROTID ARTERY INJURY; CELL PROLIFERATION; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIET SUPPLEMENTATION; ENDOTHELIUM CELL; IN VITRO STUDY; IN VIVO STUDY; KNOCKOUT MOUSE; MALE; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PRIORITY JOURNAL; WEIGHT GAIN;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIGENS, CD31; APOLIPOPROTEINS E; ATHEROSCLEROSIS; CELL LINE; CELL PROLIFERATION; CHOLESTEROL; CONNECTIVE TISSUE; DISEASE MODELS, ANIMAL; ENDOTHELIAL CELLS; HEPTANOIC ACIDS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MICE; MICE, KNOCKOUT; MICROVESSELS; NEOVASCULARIZATION, PATHOLOGIC; PYRROLES; TIME FACTORS;

EID: 79151483849     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2010.11.008     Document Type: Article

References (26)

1. Ross R. Atherosclerosis, an inflammatory disease. N Engl J Med 1999, 340:115-126.
2. Shah P.K. Mechanisms of plaque vulnerability and rupture. J Am Coll Cardiol 2003, 41:15S-22S.
3. Shepherd J., Cobbe S.M., Ford I., et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995, 333:1301-1307.
4. Zelvyte I., Dominaitiene R., Crisby M., Janciauskiene S. Modulation of inflammatory mediators and PPARgamma and NFkappaB expression by pravastatin in response to lipoproteins in human monocytes in vitro. Pharmacol Res 2002, 45:147-154.
5. Martin G., Duez H., Blanquart C., et al. Statin-induced inhibition of the Rho-signaling pathway activates PPARalpha and induces HDL apoA-I. J Clin Invest 2001, 107:1423-1432.
6. Kleemann R., Verschuren L., de Rooij B.J., et al. Evidence for anti-inflammatory activity of statins and PPARalpha activators in human C-reactive protein transgenic mice in vivo and in cultured human hepatocytes in vitro. Blood 2004, 103:4188-4194.
7. Ruiz-Velasco N., Domínguez A., Vega M.A. Statins upregulate CD36 expression in human monocytes, an effect strengthened when combined with PPAR-gamma ligands Putative contribution of Rho GTPases in statin-induced CD36 expression. Biochem Pharmacol 2004 Jan 15, 67:303-313.
8. Moulton K.S., Vakili K., Zurakowski D., et al. Inhibition of plaque neovascularization reduces macrophage accumulation and progression of advanced atherosclerosis. Proc Natl Acad Sci USA 2003, 100:4736-4741.
9. Panigrahy D., Singer S., Shen L.Q., et al. PPARgamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis. J Clin Invest 2002, 110:923-932.
10. Bishop-Bailey D., Hla T. Endothelial cell apoptosis induced by the peroxisome proliferator-activated receptor (PPAR) ligand 15-deoxy-Delta12, 14-prostaglandin J2. J Biol Chem 1999, 274:17042-17048.
11. Oitzinger W., Hofer-Warbinek R., Schmid J.A., Koshelnick Y., Binder B.R., de Martin R. Adenovirus-mediated expression of a mutant IkappaB kinase 2 inhibits the response of endothelial cells to inflammatory stimuli. Blood 2001, 97:1611-1617.
12. Scatena M., Almeida M., Chaisson M.L., Fausto N., Nicosia R.F., Giachelli C.M. NF-kappaB mediates alphavbeta3 integrin-induced endothelial cell survival. J Cell Biol 1998, 141:1083-1093.
13. Kureishi Y., Luo Z., Shiojima I., et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med 2000, 6:1004-1010.
14. Matsumura M., Fukuda N., Kobayashi N., et al. Effects of atorvastatin on angiogenesis in hindlimb ischemia and endothelial progenitor cell formation in rats. J Atheroscler Thromb 2009, 16:319-326.
15. Boodhwani M., Mieno S., Feng J., et al. Atorvastatin impairs the myocardial angiogenic response to chronic ischemia in normocholesterolemic swine. J Thorac Cardiovasc Surg 2008, 135:117-122.
16. Fu Q., Wang J., Boerma M., et al. Involvement of Heat Shock Factor 1 in statin-induced transcriptional upregulation of endothelial thrombomodulin. Circ Res 2008, 103:369-377.
17. Wilson S.H., Herrmann J., Lerman L.O., et al. Simvastatin preserves the structure of coronary adventitial vasa vasorum in experimental hypercholesterolemia independent of lipid lowering. Circulation 2002, 105:415-418.
18. Vincent L., Chen W., Hong L., et al. Inhibition of endothelial cell migration by cerivastatin, an HMG-CoA reductase inhibitor: contribution to its antiangiogenic effect. FEBS Lett 2001, 495:159-166.
19. Vincent L., Soria C., Mirshahi F., et al. Cerivastatin, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme a reductase, inhibits endothelial cell proliferation induced by angiogenic factors in vitro and angiogenesis in in vivo models. Arterioscler Thromb Vasc Biol 2002, 22:623-629.
20. Urbich C., Dernbach E., Zeiher A.M., Dimmeler S. Double-Edged Role of Statins in Angiogenesis Signaling. Circ Res 2002, 90:737-744.
21. Dulak J., Loboda A., Jazwa A., et al. Atorvastatin affects several angiogenic mediators in human endothelial cells. Endothelium 2005, 12:233-241.
22. Herrmann J., Lerman L.O., Rodriguez-Porcel M., et al. Coronary vasa vasorum neovascularization precedes epicardial endothelial dysfunction in experimental hypercholesterolemia. Cardiovasc Res 2001, 51:762-766.
23. von der Thüsen J.H., van Berkel T.J.C., Biessen E.A.L. Induction of rapid atherogenesis by perivascular carotid collar placement in apolipoprotein E-deficient and low-density lipoprotein receptor-deficient mice. Circulation 2001, 103:1164-1170.
24. Nachtigal P., Pospisilova N., Jamborova G., et al. Atorvastatin has hypolipidemic and anti-inflammatory effects in apoE/LDL receptor-double-knockout mice. Life Sci 2008, 82:708-717.
25. Bot I., de Jager S.C.A., Zernecke A., et al. Perivascular mast cells promote atherogenesis and induce plaque destabilization in apolipoprotein E-deficient mice. Circulation 2007, 115:2516-2525.
26. Wibaut-Berlaimont V., Randi A.M., Mandryko V., Lunnon M.W., Haskard D.O., Naoumova R.P. Atorvastatin affects leukocyte gene expression in dyslipidemia patients: in vivo regulation of hemostasis, inflammation and apoptosis. J Thromb Haemost 2005, 3:677-685.